All In Biotech

Drug Trial Radar · NCT07704177

Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer

A Prospective, Open-Label, Multicenter Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib for HER2-Positive or Low-Expression Locally Advanced or Metastatic Biliary Tract Cancer in the Second-Line or Later Setting

Last checked: Nov 19, 2026Latest source record: Jul 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Apr 15, 2026

Primary completion

Apr 15, 2027

Study completion Apr 15, 2028

Sponsor

Lead sponsor
Peking Union Medical College HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An investigation into the survival outcomes, progression-free survival, and safety of triple therapy with Trastuzumab Rezetecan, Adebrelimab, and Lenvatinib in patients with advanced HER2-positive/low-expressing biliary tract cancer after the failure of at least two prior systemic therapies.

Conditions

  • Biliary Tract Neoplasms Immunotherapy

Interventions

  • Trastuzumab RezetecanDrug

    The recommended dosage is 4.8 mg/kg. A fixed dose of 408 mg is administered for patients weighing ≥85 kg. It is given via intravenous infusion every 3 weeks (Q3W). The first infusion should be administered over 90 minutes. If the prior infusion was well-tolerated, subsequent infusions may be shortened to 30 minutes.

  • AdebrelimabDrug

    A fixed dose of 1200 mg is administered via intravenous infusion every 3 weeks (±3 days). The infusion duration should be controlled between 30 and 60 minutes and must not exceed 2 hours.

  • LenvatinibDrug

    Administered orally once daily with food (preferably at the same time each day). The dose is 12 mg/day for patients weighing ≥60 kg and 8 mg/day for those \<60 kg. The dose can be de-escalated based on toxicity according to the following scheme: 12 mg/day → 8 mg/day → 4 mg/day → discontinuation. If the investigator deems the patient intolerant, dose reduction across levels may be considered if deemed necessary.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rateTime frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chinese Academy of Medical Sciences & Peking Union Medical College Hospital (CAMS&PUMCH)

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.